NESBIT AWARD IN CLINICAL SCIENCE
The Histiocytosis Association, in conjunction with the Histiocyte Society, is offering an annual prize for the best clinical article at the Annual Meeting. It will be given in honor of Dr. Mark Nesbit, renowned pediatric oncologist, teacher, and supporter of the many families dealing with histiocytic disorders. The prize will be awarded to a physician or scientist who is carrying out clinical research to the therapy, biology or pathogenesis of one of the histiocytic disorders. The goal of the Award is to stimulate and promote the activities of clinical scientists from all around the world to study specific aspects of these puzzling diseases.
Dr. Mark Nesbit completed his medical training at George Washington Medical School in 1959. The remainder of his medical training was at the University of Minnesota where he specialized in pediatric hematology and oncology. In 1967 he joined the faculty at the University of Minnesota, achieving the rank of Professor of Pediatrics in 1973. Dr. Nesbit assumed the position of Director of the Division of Pediatric Hematology and Oncology at the University of Minnesota where he built one of the most productive and nationally recognized programs during his 14-year tenure. Professor Nesbit has been a leader in the development of clinical research for the treatment of leukemia and has a special interest in histiocytosis, bone tumors and the late complications of cancer survivors. In addition, Dr. Nesbit has helped countless young investigators with their careers in the field of pediatric hematology and oncology.
Of the contributions made by Professor Nesbit towards better understanding of the histiocytic disorders, we highlight the following three:
In conclusion, Dr. Nesbit has made substantial contributions to research in the field of histiocytosis. His dedication to the organization of interested investigators has resulted in a strong research agenda to better understand the etiology, diagnosis, treatment and long-term outcome of children with Langerhans cell histiocytosis. His compassion for patients and their families has always been evident, by his willingness to consult with both physicians and family members.
ANALYSIS OF C-GROUP JUVENILE XANTHOGRANULOMA FAMILY LESIONS IDENTIFIES NOVEL
KINASE ALTERATIONS AND DISTINCTIVE MORPHOLOGIC PATTERNS
MONOALLELIC MUTATIONS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (FHL): REPORT FROM THE ITALIAN REGISTRY